Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Treasury Shares (2023 - 2025)

Avidity Biosciences' Treasury Shares history spans 3 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 43.2% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, up 43.2%, while the annual FY2025 figure was $3.0 million, 43.2% up from the prior year.
  • Treasury Shares reached $3.0 million in Q4 2025 per RNA's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.0 million in Q4 2025 to a low of $607000.0 in Q1 2023.
  • Average Treasury Shares over 3 years is $1.5 million, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Treasury Shares: surged 181.47% in 2024, then surged 43.2% in 2025.
  • A 3-year view of Treasury Shares shows it stood at $750000.0 in 2023, then soared by 181.47% to $2.1 million in 2024, then soared by 43.2% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Treasury Shares are $3.0 million (Q4 2025), $2.6 million (Q1 2025), and $2.1 million (Q4 2024).